Related Experiment Video
Updated: Jun 22, 2026
06:46
Implantation of Electroencephalogram and Electrocardiogram Telemetry Devices in Neonatal Rabbit Kits
Published on: February 28, 2025
Methazolamide does not impair respiratory work performance in anesthetized rabbits
Heidrun F Kiwull-Schöne1, Yi Li, Peter J Kiwull
1Dept. of Physiology, Faculty of Medicine, Ruhr-Univ., 44780 Bochum, Germany. Heidrun.Kiwull-Schoene@rub.de
Summary
Methazolamide, a carbonic anhydrase inhibitor, enhances ventilation and does not weaken respiratory muscles, unlike acetazolamide. This suggests potential for stabilizing breathing control without muscle side effects.
Area of Science:
- Respiratory Physiology
- Pharmacology
- Neuroscience
Background:
- Carbonic anhydrase (CA) inhibitors like acetazolamide treat breathing disorders.
- Acetazolamide stabilizes respiratory control but weakens respiratory muscles.
- Methazolamide, another CA inhibitor, does not activate skeletal muscle channels, unlike acetazolamide.
Purpose of the Study:
- To investigate if methazolamide causes adverse effects on respiratory muscle performance.
- To compare methazolamide's effects on respiratory muscles with those of acetazolamide.
Main Methods:
- Anesthetized spontaneously breathing rabbits (n=7) were studied.
- Ventilation, phrenic nerve activity, and respiratory pressures were measured.
- Methazolamide was administered intravenously at two cumulative doses.
Main Results:
- Methazolamide dose-dependently enhanced baseline ventilation.
- It lowered base excess significantly.
- Respiratory muscle performance, measured by CO(2) response transmission, remained unchanged.
Conclusions:
- Methazolamide does not weaken respiratory muscles even at increased ventilatory drive.
- Methazolamide may stabilize breathing control without compromising respiratory muscle function.
- This suggests potential therapeutic applications in respiratory diseases.
